Answers are grounded in this paper and cite their sources.
Intermittent androgen deprivation was not inferior to continuous therapy with respect to the overall survival. Some quality-of-life criteria seemed improved with intermittent therapy. Intermittent androgen deprivation can be considered as an alternative option in patients with recurrent or metastatic prostate cancer.
No takes yet. Share an insight, caveat, or question.
Magnan et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: